Eye Care Company Boosts Revenue Outlook Following Record Sales Growth
Irvine, Thursday, 6 August 2026.
Driven by a 69% surge in quarterly product sales, Tarsus Pharmaceuticals raised its full-year 2026 revenue outlook to $705 million while expanding its late-stage drug pipeline.
Quarterly Revenue and Growth Metrics
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported net product sales for XDEMVY® reached $173.9 million for the quarter ended 30 June 2026 [1]. This figure represents a significant increase from the $102.66 million recorded in the same period of 2025 [1]. The year-over-year growth rate stands at 69.394 percent, confirming the company’s statement of more than 69% growth [1]. Year-to-date product sales for the first six months of 2026 totaled $319.3 million, compared to $181.0 million in the same period of 2025 [1]. The company’s total revenue for the three months ended 30 June 2026 was $173.91 million, a significant rise from $102.66 million during the same quarter in 2025 [1].
Market Expectations and Analyst Outlook
Prior to the release, analysts expected a loss of 21 cents a share on revenue of $169.5 million [2]. The actual revenue of $173.9 million exceeded these expectations, reflecting strong commercial momentum [1][2]. Wall Street remains bullish on the stock, with all nine analysts rating it a buy and setting a mean price target of $94.22 [2]. This target implies a 54.181 percent upside from the share price of $61.11 noted during the analysis period [2]. Revenue estimates had edged up modestly, rising 1.3% over 60 days leading into the report [2].
Strategic Acquisitions and Pipeline
On 6 August 2026, Tarsus announced an agreement to acquire Alkeus Pharmaceuticals, gaining the ALK-001 therapy for Stargardt disease [1]. This acquisition adds a Phase 3 clinical program targeting a condition affecting more than 36,000 U.S. patients [1]. Additionally, the company previously announced a $75 million acquisition of iRenix Medical in July, which added the late-stage asset IRX-101 to the pipeline [2]. The company is also developing TP-04 for ocular rosacea and TP-05 for Lyme disease prevention, with topline data expected in the first half of 2027 [1]. The Phase 3 COMFORT trial for IRX-101 is expected to initiate in the first half of 2027 with results in 2028 [1].
Financial Health and Investor Communication
As of 30 June 2026, the company held $449.7 million in cash, cash equivalents, and marketable securities [1]. The year-to-date net loss narrowed to $25.5 million compared to a $45.5 million loss in the same period in 2025 [1]. To discuss these results, management hosted a conference call at 5:00 a.m. PT / 8:00 a.m. ET on 6 August 2026 [3]. A recorded version of the webcast is available on the company website and will be archived for approximately 90 days [4].